Patient characteristics, including comparison based on immunosuppression status
| . | Total patients . | Immunosuppression related . | Not immunosuppression related . | P value . |
|---|---|---|---|---|
| n = 281 (%) . | n = 144 (%) . | n = 115 (%) . | ||
| Age at diagnosis (y) | Median = 55 (IQR, 44-69) | Median = 48 (IQR, 42-57) | Median = 64.9 (IQR, 52-73) | <.001 |
| ≤40 | 47 (17) | 28 (19) | 17 (15) | <.001 |
| 41-65 | 151 (54) | 99 (69) | 42 (37) | |
| >65 | 83 (30) | 17 (12) | 56 (49) | |
| Sex | ||||
| Male | 199 (71) | 104 (72) | 81 (70) | .752 |
| Female | 82 (29) | 40 (28) | 34 (30) | |
| Year of diagnosis | .112 | |||
| ≤2010 | 83 (30) | 51 (35) | 27 (23) | |
| 2011-2015 | 99 (35) | 45 (31) | 44 (38) | |
| 2016-2020 | 99 (35) | 48 (33) | 44 (38) | |
| Stage | ||||
| I | 68 (24) | 31 (22) | 33 (29) | .012 |
| II | 45 (16) | 19 (13) | 24 (21) | |
| III | 17 (6) | 11 (8) | 5 (4) | |
| IV | 143 (51) | 82 (57) | 47 (41) | |
| Not reported | 8 (3) | 1 (1) | 6 (5) | |
| HIV status | ||||
| Positive | 99 (35) | 99 (69) | 0 (0) | <.001 |
| Negative | 160 (57) | 45 (31) | 115 (100) | |
| Not tested/unknown | 22 (8) | 0 (0) | 0 (0) | |
| MYC rearrangement | ||||
| Yes | 52 (19) | 31 (22) | 19 (17) | <.001 |
| No | 41 (15) | 9 (6) | 29 (25) | |
| Not tested/unknown | 188 (67) | 104 (72) | 67 (58) | |
| EBV status | ||||
| Positive | 160 (57) | 103 (72) | 50 (43) | <.001 |
| Negative | 73 (26) | 26 (18) | 38 (33) | |
| Not tested/unknown | 48 (17) | 15 (10) | 27 (23) | |
| CD20 | ||||
| Positive | 26 (9) | 13 (9) | 11 (10) | <.001 |
| Weak | 11 (4) | 5 (3) | 5 (4) | |
| Negative | 217 (77) | 102 (71) | 98 (85) | |
| Not tested/unknown | 27 (10) | 24 (17) | 1 (1) | |
| CD30 | ||||
| Positive | 44 (16) | 21 (15) | 18 (16) | .846 |
| Negative | 116 (41) | 59 (41) | 50 (43) | |
| Not tested/unknown | 121 (43) | 64 (44) | 47 (41) | |
| BM involvement | ||||
| Yes | 51 (18) | 29 (20) | 17 (15) | .472 |
| No | 169 (60) | 89 (62) | 73 (63) | |
| Not tested/unknown | 61 (22) | 26 (18) | 25 (22) | |
| CNS involvement | ||||
| Yes | 13 (5) | 9 (6) | 3 (3) | .005 |
| No | 183 (65) | 105 (73) | 68 (59) | |
| Not tested/unknown | 85 (30) | 30 (21) | 44 (38) | |
| Location of primary tumor | ||||
| Oropharynx/nasopharynx/orbit | 79 (28) | 38 (26) | 40 (35) | .101 |
| Other site | 181 (64) | 93 (65) | 71 (62) | |
| Not reported/unknown | 21 (7) | 13 (9) | 4 (3) | |
| LDH level | ||||
| Elevated | 155 (55) | 82 (57) | 62 (54) | .458 |
| Not elevated | 87 (31) | 42 (29) | 41 (36) | |
| Not tested/unknown | 39 (14) | 20 (14) | 12 (10) | |
| ECOG performance status | ||||
| ≤1 | 182 (65) | 89 (62) | 87 (76) | .046 |
| >1 | 84 (30) | 48 (33) | 26 (23) | |
| Not reported | 15 (5) | 7 (5) | 2 (2) | |
| Frontline treatment | ||||
| High intensity | 75 (27) | 38 (26) | 32 (28) | .837 |
| Standard intensity | 159 (57) | 86 (60) | 68 (59) | |
| Other | 43 (15) | 19 (13) | 15 (13) | |
| Not reported | 4 (1) | 1 (1) | 0 (0) | |
| Rituximab | ||||
| Yes | 45 (16) | 23 (16) | 22 (19) | .505 |
| No | 236 (84) | 121 (84) | 93 (81) | |
| PI-containing regimen | ||||
| Yes | 33 (12) | 14 (10) | 19 (17) | .066 |
| No | 205 (73) | 90 (63) | 76 (66) | |
| Not reported | 43 (15) | 40 (28) | 20 (17) | |
| ASCT in first line | ||||
| Yes | 13 (5) | 3 (2) | 10 (9) | .016 |
| No | 268 (95) | 141 (98) | 105 (91) | |
| IPI | ||||
| Low risk | 76 (27) | 40 (28) | 34 (30) | .406 |
| Low-intermediate risk | 49 (17) | 21 (15) | 25 (22) | |
| High-intermediate risk | 68 (24) | 36 (25) | 29 (25) | |
| High risk | 36 (13) | 20 (14) | 10 (9) | |
| Not reported | 52 (19) | 27 (19) | 17 (15) |
| . | Total patients . | Immunosuppression related . | Not immunosuppression related . | P value . |
|---|---|---|---|---|
| n = 281 (%) . | n = 144 (%) . | n = 115 (%) . | ||
| Age at diagnosis (y) | Median = 55 (IQR, 44-69) | Median = 48 (IQR, 42-57) | Median = 64.9 (IQR, 52-73) | <.001 |
| ≤40 | 47 (17) | 28 (19) | 17 (15) | <.001 |
| 41-65 | 151 (54) | 99 (69) | 42 (37) | |
| >65 | 83 (30) | 17 (12) | 56 (49) | |
| Sex | ||||
| Male | 199 (71) | 104 (72) | 81 (70) | .752 |
| Female | 82 (29) | 40 (28) | 34 (30) | |
| Year of diagnosis | .112 | |||
| ≤2010 | 83 (30) | 51 (35) | 27 (23) | |
| 2011-2015 | 99 (35) | 45 (31) | 44 (38) | |
| 2016-2020 | 99 (35) | 48 (33) | 44 (38) | |
| Stage | ||||
| I | 68 (24) | 31 (22) | 33 (29) | .012 |
| II | 45 (16) | 19 (13) | 24 (21) | |
| III | 17 (6) | 11 (8) | 5 (4) | |
| IV | 143 (51) | 82 (57) | 47 (41) | |
| Not reported | 8 (3) | 1 (1) | 6 (5) | |
| HIV status | ||||
| Positive | 99 (35) | 99 (69) | 0 (0) | <.001 |
| Negative | 160 (57) | 45 (31) | 115 (100) | |
| Not tested/unknown | 22 (8) | 0 (0) | 0 (0) | |
| MYC rearrangement | ||||
| Yes | 52 (19) | 31 (22) | 19 (17) | <.001 |
| No | 41 (15) | 9 (6) | 29 (25) | |
| Not tested/unknown | 188 (67) | 104 (72) | 67 (58) | |
| EBV status | ||||
| Positive | 160 (57) | 103 (72) | 50 (43) | <.001 |
| Negative | 73 (26) | 26 (18) | 38 (33) | |
| Not tested/unknown | 48 (17) | 15 (10) | 27 (23) | |
| CD20 | ||||
| Positive | 26 (9) | 13 (9) | 11 (10) | <.001 |
| Weak | 11 (4) | 5 (3) | 5 (4) | |
| Negative | 217 (77) | 102 (71) | 98 (85) | |
| Not tested/unknown | 27 (10) | 24 (17) | 1 (1) | |
| CD30 | ||||
| Positive | 44 (16) | 21 (15) | 18 (16) | .846 |
| Negative | 116 (41) | 59 (41) | 50 (43) | |
| Not tested/unknown | 121 (43) | 64 (44) | 47 (41) | |
| BM involvement | ||||
| Yes | 51 (18) | 29 (20) | 17 (15) | .472 |
| No | 169 (60) | 89 (62) | 73 (63) | |
| Not tested/unknown | 61 (22) | 26 (18) | 25 (22) | |
| CNS involvement | ||||
| Yes | 13 (5) | 9 (6) | 3 (3) | .005 |
| No | 183 (65) | 105 (73) | 68 (59) | |
| Not tested/unknown | 85 (30) | 30 (21) | 44 (38) | |
| Location of primary tumor | ||||
| Oropharynx/nasopharynx/orbit | 79 (28) | 38 (26) | 40 (35) | .101 |
| Other site | 181 (64) | 93 (65) | 71 (62) | |
| Not reported/unknown | 21 (7) | 13 (9) | 4 (3) | |
| LDH level | ||||
| Elevated | 155 (55) | 82 (57) | 62 (54) | .458 |
| Not elevated | 87 (31) | 42 (29) | 41 (36) | |
| Not tested/unknown | 39 (14) | 20 (14) | 12 (10) | |
| ECOG performance status | ||||
| ≤1 | 182 (65) | 89 (62) | 87 (76) | .046 |
| >1 | 84 (30) | 48 (33) | 26 (23) | |
| Not reported | 15 (5) | 7 (5) | 2 (2) | |
| Frontline treatment | ||||
| High intensity | 75 (27) | 38 (26) | 32 (28) | .837 |
| Standard intensity | 159 (57) | 86 (60) | 68 (59) | |
| Other | 43 (15) | 19 (13) | 15 (13) | |
| Not reported | 4 (1) | 1 (1) | 0 (0) | |
| Rituximab | ||||
| Yes | 45 (16) | 23 (16) | 22 (19) | .505 |
| No | 236 (84) | 121 (84) | 93 (81) | |
| PI-containing regimen | ||||
| Yes | 33 (12) | 14 (10) | 19 (17) | .066 |
| No | 205 (73) | 90 (63) | 76 (66) | |
| Not reported | 43 (15) | 40 (28) | 20 (17) | |
| ASCT in first line | ||||
| Yes | 13 (5) | 3 (2) | 10 (9) | .016 |
| No | 268 (95) | 141 (98) | 105 (91) | |
| IPI | ||||
| Low risk | 76 (27) | 40 (28) | 34 (30) | .406 |
| Low-intermediate risk | 49 (17) | 21 (15) | 25 (22) | |
| High-intermediate risk | 68 (24) | 36 (25) | 29 (25) | |
| High risk | 36 (13) | 20 (14) | 10 (9) | |
| Not reported | 52 (19) | 27 (19) | 17 (15) |
Bold values are statistically significant.